SCHEMBL1345002

SCHEMBL1345002

CCOC(=O)C(=CNc1cc(F)c(F)c(F)c1)C(=O)OCC

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 5/20 0.61
NPSR1 Q6W5P4 4/20 0.58
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
GAA P10253 3/20 0.51
MAPT P10636 7/20 0.51
KDM4E B2RXH2 6/20 0.51
TDP1 Q9NUW8 2/20 0.51
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
MAPK1 P28482 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
RECQL P46063 1/20 0.46
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25357063 0.88 DHODH (0.58) DHODHNPSR1MEN1KMT2AGAA
SCHEMBL25069374 0.86 DHODH (0.63) DHODHNPSR1MEN1KMT2AGAA
SCHEMBL14341439 0.85 DHODH (0.67) DHODHNPSR1MEN1KMT2AGAA
SCHEMBL10511749 0.84 MEN1 (0.58) DHODHNPSR1MEN1KMT2AGAA
SCHEMBL10863268 0.83 DHODH (0.71) DHODHNPSR1MEN1KMT2AGAA
SCHEMBL14845097 0.83 DHODH (0.52) DHODHNPSR1MEN1KMT2AGAA
SCHEMBL25999700 0.83 DHODH (0.52) DHODHNPSR1MEN1KMT2AGAA
SCHEMBL31080679 0.82 DHODH (0.62) DHODHNPSR1MEN1KMT2AGAA
SCHEMBL29705221 0.82 DHODH (0.62) DHODHNPSR1MEN1KMT2AGAA
SCHEMBL17241561 0.82 DHODH (0.62) DHODHNPSR1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230058189-A1 QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME Frequency Therapeutics, Inc. (US) 2023-02-23 US disclosed
US-8063221-B2 Aminoquinolones as GSK-3 inhibitors KYORIN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
EP-2383271-A1 Aminoquinolones as GSK-3 Inhibitors Kyorin Pharmaceutical Co., Ltd. (JP) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230058189-A1 QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME DCX, NES, MCL1 DHODH 1291/4885NPSR1 2393/4885MEN1 654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.